Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
IVAX Receives Tentative Approval For Nefazodone HCI Tablets


MIAMI, Jun 18, 2003 (BUSINESS WIRE) -- IVAX Corporation (AMEX: IVX) (LSE:IVX.L)
announced today that it has received tentative approval from the FDA for its
Abbreviated New Drug Application (ANDA) for nefazodone hydrochloride tablets in
50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths. Upon final approval, this
product will be sold through the company's wholly owned subsidiary, IVAX
Pharmaceuticals, Inc. Nefazodone hydrochloride tablets are the generic
equivalent of Serzone(R) tablets, marketed by Bristol-Myers Squibb for the
treatment of depression. U.S. sales of Serzone for the past twelve months,
ending with the first quarter of 2003, were $237 million.

IVAX currently has 39 ANDAs pending at the FDA. The company continues its
aggressive filing schedule for new ANDA submissions.

IVAX Corporation, headquartered in Miami, Florida, discovers, develops,
manufactures, and markets branded and brand equivalent (generic) pharmaceuticals
and veterinary products in the U.S. and internationally.

Copies of this and other news releases may be obtained free of charge from IVAX'
website at http://www.ivax.com.



Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement